Journal article · 2012 · Open access

An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure

Douglas J. Taylor, Anneke C Grobler, Salim S. Abdool Karim

Clinical Trials, 9(4), 377–384 · Published 18 May 2012 · DOI 10.1177/1740774512445512

Open PDFView at the publisherCite this paper

In brief

“An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure” is a 2012 journal article by Douglas J. Taylor and 2 co-authors, published in Clinical Trials. OpenAlex counts 2 citations as of 19 November 2026. It is open access: the full text is free to read at ResearchSpace (University of KwaZulu-Natal).

Citations
2
Most cited in
2013 (1)
Field-weighted impact
0.46
References
17
Authors
3

Abstract

BACKGROUND: Vaginally and rectally applied microbicides are being developed to help prevent sexual acquisition of HIV. Due to the lack of surrogate outcomes, the path toward licensure typically moves directly from expanded safety studies to expensive Phase 2b/3 trials with rare incident infection outcomes. The need to confirm an initial trial's significant finding can lead to serious delays in implementing essential programs to reduce the spread of HIV. PURPOSE: To propose an adaptive design where a Phase 2b/3 study powered to detect a clinically meaningful effect with evidence of one trial (observing one-sided p < 0.025) is allowed to expand by a prespecified, feasible amount if interim data suggest the chance of further achieving a more robust evidence threshold (p < 0.001, potentially sufficient for licensure from a single trial) is promising. METHODS: As an example, prespecified conditional power criteria are used to determine whether a 90-event trial with 90% power to detect a 50% reduction in risk should be expanded to 130 events. Asymptotic results and simulations are used to assess false-positive error rates and other operating characteristics of the design. RESULTS: False-positive error rates can be controlled at the desired 0.025 and 0.001 levels with appropriate choice of critical values or expansion criteria. The chance of achieving robust evidence can approach that of a 130-event trial with traditional stopping boundaries (controlling a = 0.001) but with substantially lower expected size for plausible effectiveness levels. LIMITATIONS: Conditional power calculations assume the interim estimate of effect is an unbiased estimate for the remainder of the trial, an assumption which may not hold if product adherence varies over time. Observing a measure of effect with p < 0.001 may not be sufficient for licensure. A decision to expand the trial would be informative to investigators regarding the interim effect size. CONCLUSIONS: A moderate increase in trial size can make the difference between a study with good power to detect a clinically meaningful effect and one which may reasonably obtain the robust evidence required for regulatory bodies and public health programs to consider making a new microbicide available to persons at risk of HIV infection. The proposed design allows for this possibility while not requiring investigators to make an up-front commitment to a prohibitively large trial.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Taylor, D. J., Grobler, A. C., & Karim, S. S. A. (2012). An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Clinical Trials, 9(4), 377–384. https://doi.org/10.1177/1740774512445512

MLA 9

Taylor, Douglas J., et al. “An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.” Clinical Trials, vol. 9, no. 4, 2012, pp. 377–384. https://doi.org/10.1177/1740774512445512.

Chicago

Taylor, Douglas J., Anneke C Grobler, and Salim S. Abdool Karim. 2012. “An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.” Clinical Trials 9 (4): 377–384. https://doi.org/10.1177/1740774512445512.

Harvard

Taylor, D. J., Grobler, A. C. and Karim, S. S. A. (2012) ‘An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure’, Clinical Trials, 9(4), pp. 377–384. doi:10.1177/1740774512445512.

IEEE

D. J. Taylor, A. C. Grobler, and S. S. A. Karim, “An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure,” Clinical Trials, vol. 9, no. 4, pp. 377–384, 2012, doi: 10.1177/1740774512445512.

BibTeX

@article{taylor2012adaptive,
  title     = {{An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure}},
  author    = {Taylor, Douglas J. and Grobler, Anneke C and Karim, Salim S. Abdool},
  journal   = {Clinical Trials},
  year      = {2012},
  volume    = {9},
  number    = {4},
  pages     = {377--384},
  doi       = {10.1177/1740774512445512},
  url       = {https://doi.org/10.1177/1740774512445512}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials

  • adaptive trial design
  • microbicides
  • HIV prevention
  • conditional power
  • interim analysis
  • false positive rate
  • surrogate endpoints
  • sample size

Work with this paper

Most-cited papers in Mathematics

All highly cited Mathematics papers

Questions about this paper

How do I cite this paper in APA style?

Taylor, D. J., Grobler, A. C., & Karim, S. S. A. (2012). An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Clinical Trials, 9(4), 377–384. https://doi.org/10.1177/1740774512445512

How many times has this paper been cited?

2 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at ResearchSpace (University of KwaZulu-Natal): sign in and open the PDF from this page.

Who wrote this paper?

Douglas J. Taylor, Anneke C Grobler, Salim S. Abdool Karim.

What is the DOI of this paper?

10.1177/1740774512445512, permanently at https://doi.org/10.1177/1740774512445512. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.